| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $2,804 | 1 | 50 |
Sells | $7,300 | 1 | 50 |
| Lialin Tony Serge | Chief Commercial Officer | 1 | $2,804 | 0 | $0 | $2,804 |
| Gobel David | director | 0 | $0 | 1 | $7,300 | $-7,300 |
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as …
Over the last 12 months, insiders at VivoSim Labs, Inc. have bought $2,804 and sold $7,300 worth of VivoSim Labs, Inc. stock.
On average, over the past 5 years, insiders at VivoSim Labs, Inc. have bought $2,804 and sold $7,300 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lialin Tony Serge (Chief Commercial Officer) — $2,804.
The last purchase of 10,000 shares for transaction amount of $2,804 was made by Lialin Tony Serge (Chief Commercial Officer) on 2026‑08‑31.
| 2026-08-31 | Lialin Tony Serge | Chief Commercial Officer | 10,000 0.1837% | $0.28 | $2,804 | -30.51% | ||
| 2025-11-17 | Sale | Gobel David | director | 3,266 0.1369% | $2.24 | $7,300 | -40.79% |
| Increased Positions | 8 | +21.05% | 27,813 | +12.6% |
| Decreased Positions | 12 | -31.58% | 144,007 | -65.23% |
| New Positions | 5 | New | 19,619 | New |
| Sold Out Positions | 7 | Sold Out | 117,409 | Sold Out |
| Total Postitions | 34 | -10.53% | 104,569 | -52.63% |